03:56 AM EDT, 07/05/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Thursday its partner Viatris Pharmaceutical Japan has launched a phase 3 clinical trial in Japan of Nefecon as a potential treatment for Japanese patients with IgA nephropathy, a disease of the kidney and the immune system.

Calliditas licenses Nefecon, which is called VR-205 in Japan, to Viatris as a specialty therapy for IgA nephropathy.

The testing will allow a limited number of Japanese patients to participate in a study parallel to the global NefIgArd trial.

Price: 39.74, Change: +0.51, Percent Change: +1.30